Effects of the Edaravone, a Drug Approved for the Treatment of Amyotrophic Lateral Sclerosis, on Mitochondrial Function and Neuroprotection
Edaravone, the first known free radical scavenger, has demonstrated cellular protective properties in animals and humans. Owing to its antioxidant activity, edaravone modulates oxidative damage in various diseases, especially neurodegenerative diseases. In 2015, edaravone was approved in Japan to tr...
Hlavní autoři: | Sun Joo Cha, Kiyoung Kim |
---|---|
Médium: | Článek |
Jazyk: | English |
Vydáno: |
MDPI AG
2022-01-01
|
Edice: | Antioxidants |
Témata: | |
On-line přístup: | https://www.mdpi.com/2076-3921/11/2/195 |
Podobné jednotky
-
A New Treatment Option for Amyotrophic Lateral Sclerosis: Edaravone
Autor: Erdi Şahin
Vydáno: (2018-03-01) -
Edaravone: A new hope for patients with amyotrophic lateral sclerosis
Autor: Shivangi Garg, a další
Vydáno: (2019-01-01) -
Improved Long-Term Survival with Edaravone Therapy in Patients with Amyotrophic Lateral Sclerosis: A Retrospective Single-Center Study in Japan
Autor: Hideki Houzen, a další
Vydáno: (2021-07-01) -
Long-term outcomes of edaravone in amyotrophic lateral sclerosis in South Korea: 72-week observational study
Autor: Jin-Mo Park, a další
Vydáno: (2022-07-01) -
Cost-utility analysis for sublingual versus intravenous edaravone in the treatment of amyotrophic lateral sclerosis
Autor: Chang Liu, a další
Vydáno: (2024-10-01)